Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients

Back to Search
Print
Bookmark Trial

NCT00556257

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Kidney Transplantation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Recipient of first time kidney transplant

- Between the ages of 18 and 70 years, inclusive

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Recipient of any non-kidney transplant

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Kidney TransplantationStudy Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients
NCT00519116
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Kidney TransplantationCollection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients
NCT01375127
  1. Los Angeles, California
  2. Los Angeles, California
  3. Palo Alto, California
  4. San Francisco, California
  5. San Francisco, California
  6. Stanford, California
  7. Aurora, Colorado
  8. Tampa, Florida
  9. Chicago, Illinois
  10. Chicago, Illinois
  11. Boston, Massachusetts
  12. Springfiled, Massachusetts
  13. Ann Arbor, Michigan
  14. Detroit, Michigan
  15. St. Louis, Missouri
  16. Livingston, New Jersey
  17. New York, New York
  18. Valhalla, New York
  19. Chapel Hill, North Carolina
  20. Dallas, Texas
  21. Dallas, Texas
  22. Fort Worth, Texas
  23. Richmond, Virginia
  24. Camperdown, New South Wales
  25. Westmead, New South Wales
  26. Adelaide, South Australia
  27. Clayton, Victoria
  28. Parkville, Victoria
  29. Anderlecht,
  30. Porto Alegre, RS
  31. Sao Paulo, SP
  32. Edmonton, Alberta
  33. Praha 4 - Krc,
  34. Nantes Cedex 1,
  35. Paris Cedex 15,
  36. Toulouse Cedex 9,
  37. Berlin,
  38. Hamburg,
  39. Roma,
  40. Rotterdam,
  41. Oslo,
  42. L'Hospitalet de Llobregat, Barcelona
  43. Barcelona,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Kidney TransplantationA 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
NCT00106639
  1. Los Angeles, California
  2. Los Angeles, California
  3. Palo Alto, California
  4. San Diego, California
  5. San Francisco, California
  6. San Francisco, California
  7. Stanford, California
  8. Denver, Colorado
  9. Chicago, Illinois
  10. New Orleans, Louisiana
  11. St. Louis, Missouri
  12. St. Louis, Missouri
  13. Livingston, New Jersey
  14. New York, New York
  15. New York, New York
  16. Portland, Oregon
  17. Dallas, Texas
  18. Dallas, Texas
  19. Richmond, Virginia
  20. Milwaukee, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Kidney TransplantationStudy of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
NCT00483756
  1. Little Rock, Arkansas
  2. Los Angeles, California
  3. Los Angeles, California
  4. Palo Alto, California
  5. San Diego, California
  6. San Francisco, California
  7. San Francisco, California
  8. Stanford, California
  9. Aurora, Colorado
  10. New Haven, Connecticut
  11. New Haven, Connecticut
  12. Gainesville, Florida
  13. Gainsville, Florida
  14. Tampa, Florida
  15. Chicago, Illinois
  16. Chicago, Illinois
  17. Baltimore, Maryland
  18. Boston, Massachusetts
  19. Springfield, Massachusetts
  20. Springfield, Massachusetts
  21. Ann Arbor, Michigan
  22. Detroit, Michigan
  23. Rochester, Minnesota
  24. St. Louis, Missouri
  25. Livingston, New Jersey
  26. New York, New York
  27. Valhalla, New York
  28. Chapel Hill, North Carolina
  29. Chapel Hill, North Carolina
  30. Chapel Hill, North Carolina
  31. Chapel Hill, North Carolina
  32. Portland, Oregon
  33. Philadelphia, Pennsylvania
  34. Charleston, South Carolina
  35. Dallas, Texas
  36. Dallas, Texas
  37. Fort Worth, Texas
  38. Camperdown, New South Wales
  39. Westmead, New South Wales
  40. Adelaide, South Australia
  41. Woodville, South Australia
  42. Clayton, Victoria
  43. Parkville, Victoria
  44. Anderlecht,
  45. Leuven,
  46. Porto Alegre, RS
  47. Sao Paulo, SP
  48. Sao Paulo, SP
  49. Edmonton, Alberta
  50. Praha 4,
  51. Nantes,
  52. Paris Cedex 15,
  53. Toulouse Cedex 9,
  54. Vandoeuvre Les Nancy,
  55. Berlin,
  56. Hamburg,
  57. Bologna,
  58. Roma,
  59. Seoul,
  60. Seoul,
  61. Seoul,
  62. Rotterdam,
  63. Oslo,
  64. Warszawa,
  65. Wroclaw,
  66. Coimbra,
  67. Lisboa,
  68. Hospitalet de Llobregat, Barcelona
  69. Barcelona,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients
Official Title  ICMJE A Pilot Randomized, Multicenter, Open-Label, Active Comparator-Controlled Trial Of A CP-690,550-Based Regimen In De Novo Kidney Allograft Recipients
Brief Summary A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Kidney Transplantation
Intervention  ICMJE
  • Drug: Cyclosporine
    Standard of care
  • Drug: CP-690-,550
    CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
Study Arms  ICMJE
  • Active Comparator: Treatment Arm 1
    Treatment Arm 1 will also receive standard of care medications.
    Intervention: Drug: Cyclosporine
  • Experimental: Treatment Arm 2
    Treatment Arm 2 will also receive select standard of care medications.
    Intervention: Drug: CP-690-,550
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: May 27, 2008)		0
Original Estimated Enrollment  ICMJE
 (submitted: November 8, 2007)		32
Study Completion Date  ICMJE Not Provided
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Recipient of first time kidney transplant
  • Between the ages of 18 and 70 years, inclusive

Exclusion Criteria:

  • Recipient of any non-kidney transplant
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries United States
 
Administrative Information
NCT Number  ICMJE NCT00556257
Other Study ID Numbers  ICMJE A3921037
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP